Use this URL to cite or link to this record in EThOS:
Title: Novel mechanisms for increased cardiovascular risk in chronic obstructive pulmonary disease
Author: Maclay, John David
Awarding Body: University of Edinburgh
Current Institution: University of Edinburgh
Date of Award: 2012
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Chronic obstructive pulmonary disease (COPD) is a significant burden on individuals with the disease and on healthcare resources. By 2020 it is projected to be the third leading cause of death worldwide. COPD is a condition that is characterised by chronic lung inflammation and damage. However, it is now known that COPD not only affects the lungs, but also has systemic associations, effects and consequences. These include osteoporosis, skeletal muscle wasting and dysfunction, depression, anaemia, systemic inflammation and cardiovascular disease. Population based studies have identified that COPD is a risk factor for cardiovascular morbidity and mortality, independent of traditional risk factors including cigarette smoking. The mechanisms responsible for this association have yet to be established. In the studies in this thesis, I investigated a number of novel mechanisms that may contribute to the increased cardiovascular risk in COPD. It is thought that the lowgrade systemic inflammation associated with COPD may have a role to play. In addition, the enhanced systemic inflammatory response in exacerbations of COPD may predispose these individuals to cardiovascular events. Activation of platelets and interaction between platelets and monocytes are early processes in the pathogenesis of atherothrombosis. I therefore measured markers of platelet activation in patients with COPD and healthy controls. In a second study, platelet activation was measured in patients admitted to hospital with an exacerbation of COPD and in convalescence. Patients with COPD had higher platelet-monocyte aggregation in comparison to controls matched for age and cigarette smoke exposure. This was further increased during exacerbations. In addition to platelet activation, vascular dysfunction predisposes to cardiovascular morbidity and mortality. I undertook comprehensive assessments of vascular function (arterial stiffness, endothelial vasomotor function and endogenous fibrinolysis) in patients with COPD and healthy ex-smoking controls. I confirmed that patients with COPD have increased arterial stiffness independent of cigarette smoking. However, contrary to prior popular assumption, endothelial vasomotor and fibrinolytic function were not impaired in comparison to healthy controls matched for smoking history. We had previously reported an association between emphysema severity and arterial stiffness. I hypothesised that the mechanism for this association in COPD patients may be increased elastin degradation, not only in the lungs, but also in the large arteries. To test the hypothesis that COPD is a condition with systemic elastin degradation, I measured elastin degradation in skin biopsies from patients with COPD and healthy controls. There was increased cutaneous elastin degradation in COPD patients. In addition, there was increased expression of matrix metalloproteinases in COPD skin biopsies, which may be a mechanism for this observation. Furthermore, emphysema severity and arterial stiffness were associated with cutaneous elastin degradation. These studies have identified platelet activation and arterial stiffness as novel mechanisms for the development of cardiovascular disease in COPD. Platelet inhibition and improvement of vascular function represent plausible targets for the prevention of cardiovascular events in this population. In addition, I have provided evidence for elastin degradation as a systemic effect of COPD and that systemic upregulation of matrix metalloproteinases may be the unifying mechanism for this. Focus on inflammatory pathways that result in this will provide more insight into the pathogenesis of COPD and help direct future therapies.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (M.D.) Qualification Level: Doctoral
EThOS ID:  DOI: Not available